Trial · NCT07909031
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07909031, Phase 1, Phase 2, Recruiting, Crescent Biopharma, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors. Trials, record NCT07909031. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909031
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- NCT number
- NCT07909031
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 219 participants, estimated
- Lead sponsor
- Crescent Biopharma, Inc.
- Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC), Esophageal Squamous Cell Carcinoma (ESCC), Ovarian Cancer, Endometrial Cancer, Cervical Cancer Metastatic, Non-small Cell Lung Cancer (NSCLC)
- Interventions
- CR-002
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1: Dose Escalation - incidence and nature of dose-limiting toxicities | From the first dose of study drug up until approximately 1 month | Per cohort |
| Primary | Part 1: Dose Escalation - characterization of the maximum tolerated dose, if applicable | From the first dose of study drug up until approximately 1 month | Per cohort |
| Primary | All Parts - incidence, nature, and severity of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events | From the first dose of study drug until 90 days after the last dose of study drug | Events are graded according to National Cancer Institute Cancer Terminology Criteria for Adverse Events (NCI CTCAE) |
| Primary | All Parts - incidence and severity of TEAEs leading to dose modifications | From the first dose of study drug until 90 days after the last dose of study drug | |
| Primary | All Parts - incidence and severity of TEAEs leading to treatment discontinuation | From the first dose of study drug until 90 days after the last dose of study drug | |
| Secondary | All Parts - determination of recommended phase 2 dose(s) | From the first dose of study drug until 90 days after the last dose of study drug | |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | AUC0-inf after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | AUClast after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | Cmax after a single dose and steady state parameters, as appropriate |
| Secondary | All Parts - serum CR-002 pharmacokinetic parameters | Predose until up to approximately 36 months | Tmax after a single dose and steady state parameters, as appropriate |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909031
GET https://conductscience.org/api/trials/v1/NCT07909031/registered?page=2